James DArecca - May 17, 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP, Chief Financial Officer
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca
Stock symbol
HAE
Transactions as of
May 17, 2024
Transactions value $
$0
Form type
4
Date filed
5/21/2024, 05:41 PM
Previous filing
May 17, 2024
Next filing
Aug 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +4.44K +34.39% 17.3K May 17, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +9.76K $0.00 9.76K May 17, 2024 Common Stock 9.76K $95.73 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 This number includes unvested RSUs previously reported.
F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.